Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation

NCT00029328 is registered in ClinicalTrials.gov with FDA Office of Orphan Products Development as lead sponsor.

NCT NCT00029328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00029328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
Lead sponsor
FDA Office of Orphan Products Development
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2001
Completion date
September 30, 2003
Enrollment
15
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bronchiolitis obliterans, pneumonia, respiratory distress syndrome, adult